LifeArc and DEBRA Austria launch £2.5 million funding call for repurposing therapies for epidermolysis bullosa
10. Juli 2023 07:59 ET
|
LifeArc
LifeArc and DEBRA Austria launch £2.5 million funding callfor repurposing therapies for epidermolysis bullosa New call for projects for treatments that could be repurposed to treat epidermolysis...
Global Epidermolysis Bullosa Market to Surpass US$ 8,008.50 Million by 2030, Says Coherent Market Insights (CMI)
13. Februar 2023 10:00 ET
|
CMI
Burlingame, Feb. 13, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global epidermolysis bullosa market is estimated to be valued at US$ 3,429.30 million in 2022 and expected to...
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
25. Juli 2022 07:30 ET
|
InMed Pharmaceuticals Inc.
Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety dataFirst adolescent patient with EB enrolled into clinical trial and completed treatment...
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
26. Oktober 2021 07:00 ET
|
Krystal Biotech, Inc.
Topline results anticipated in the fourth quarter of 2021Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint...
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
30. September 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare...
DelveInsight Highlights Major Advances, Transformative Therapies and Leading Players Wheeling the Dystrophic Epidermolysis Bullosa Pipeline Landscape
30. Juni 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, June 30, 2021 (GLOBE NEWSWIRE) -- DelveInsight Highlights Major Advances, Transformative Therapies and Leading Players Wheeling the Dystrophic Epidermolysis Bullosa Pipeline...
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa
28. April 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 creamAdditional submissions slated for France, Germany, Greece, and Italy over the next several days and...
Epidermolysis bullosa pipeline anticipated to offer several novel pipeline therapies in the next decade
12. Januar 2021 12:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Epidermolysis bullosa pipeline anticipated to offer several novel pipeline therapies in the next decade The Epidermolysis bullosa clinical...
AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103
15. September 2020 07:00 ET
|
Amryt Pharma Plc
AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103 DUBLIN, Ireland, and Boston MA, September 15 2020, Amryt (Nasdaq: AMYT,...
EB Research Partnership Announces New $3 Million Gift from the Ann & Ari Deshe Family
07. November 2019 09:00 ET
|
EB Research Partnership
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), the largest 501(c)(3) nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis...